tbuckley/cabot-search huggingface dataset:
Prelymphoid Leukemia Phase of Rauscher Virus Infection&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Brodsky, Isadore, Kahn, S. Benham, Ross, Evelyn M., Petkov, Goldie, Braverman, Shirley D.
Journal: JNCI Journal of the National Cancer Institute (1967)

Journal Article Prelymphoid Leukemia Phase of Rauscher Virus Infection Get access Isadore Brodsky, M.D., Isadore Brodsky, M.D. Hematology Section, Department of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania 19102 Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Benham Kahn, M.D., S. Benham Kahn, M.D. Hematology Section, Department of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania 19102 Search for other works by this author on: Oxford Academic PubMed Google Scholar Evelyn M. Ross, Evelyn M. Ross Hematology Section, Department of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania 19102 Search for other works by this author on: Oxford Academic PubMed Google Scholar Goldie Petkov, B.S., Goldie Petkov, B.S. Hematology Section, Department of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania 19102 Search for other works by this author on: Oxford Academic PubMed Google Scholar Shirley D. Braverman, M.S. Shirley D. Braverman, M.S. Hematology Section, Department of Medicine, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania 19102 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 38, Issue 5, May 1967, Pages 779–787, https://doi.org/10.1093/jnci/38.5.779 Published: 01 May 1967 Article history Received: 25 October 1966 Published: 01 May 1967
Psychotherapy of borderline patients: the influence of theory on technique
Authors: H J Friedman
Journal: American Journal of Psychiatry (1975)

Although the treatment of borderline patients has attracted increased attention, there is little agreement on the basic nature of the disorder or the proper techniques for its treatment by analytically oriented psychotherapy. The author states that treatment based on the idea that the borderline patient achieves therapeutic gains by raging against an accepting therapist for a prolonged period of time is not so effective as treatment based on the recognition of specific ego defects as the core pathology. He suggests that the therapist be active in the treatment of borderline patients and not permit gross and unproductive distortions of the therapeutic relationship.
Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK: a population-based cross-sectional study
Authors: Robert W Aldridge, Dominik Zenner, Peter J White, Morris C Muzyamba, Miranda Loutet, Poonam Dhavan, Davide Mosca, Andrew C Hayward, Ibrahim Abubakar
Journal: The Lancet Infectious Diseases (2016)

An increasing number of countries with low incidence of tuberculosis have pre-entry screening programmes for migrants. We present the first estimates of the prevalence of and risk factors for tuberculosis in migrants from 15 high-incidence countries screened before entry to the UK.We did a population-based cross-sectional study of applicants for long-term visas who were screened for tuberculosis before entry to the UK in a pilot programme between Oct 1, 2005, and Dec 31, 2013. The primary outcome was prevalence of bacteriologically confirmed tuberculosis. We used Poisson regression to estimate crude prevalence and created a multivariable logistic regression model to identify risk factors for the primary outcome.476 455 visa applicants were screened, and the crude prevalence of bacteriologically confirmed tuberculosis was 92 (95% CI 84-101) per 100 000 individuals. After adjustment for age and sex, factors that were strongly associated with an increased risk of bacteriologically confirmed disease at pre-entry screening were self-report of close or household contact with an individual with tuberculosis (odds ratio 11·6, 95% CI 7·0-19·3; p<0·0001) and being an applicant for settlement and dependant visas (1·3, 1·0-1·6; p=0·0203).Migrants reporting contact with an individual with tuberculosis had the highest risk of tuberculosis at pre-entry screening. To tackle this disease burden in migrants, a comprehensive and collaborative approach is needed between countries with pre-entry screening programmes, health services in the countries of origin and migration, national tuberculosis control programmes, and international public health bodies.Wellcome Trust, Medical Research Council, and UK National Institute for Health Research.
Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma
Authors: Katherine J. Ransohoff, Kavita Y. Sarin, Jean Y. Tang
Journal: Journal of Clinical Oncology (2015)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2015.62.2225 Journal of Clinical Oncology - published online before print July 20, 2015 PMID: 26195713 Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma Katherine J. RansohoffxKatherine J. RansohoffSearch for articles by this author , Kavita Y. SarinxKavita Y. SarinSearch for articles by this author , Jean Y. TangxJean Y. TangSearch for articles by this author Show More Stanford University, Stanford, CA https://doi.org/10.1200/JCO.2015.62.2225 First Page Full Text PDF Figures and Tables © 2015 by American Society of Clinical Oncology
Evesor the First Model-Based Multi-Parameter Phase 1 Trial Meant to Optimize the Benefit/Toxicity Ratio of Everolimus and Sorafenib Association: Preliminary Pd Outcomes
Authors: M.A. Mohamed, E. Henin, G. Freyer, M. Tod, C. Rodriguez-Lafrasse, P. Valette, P. Cassier, J.H. Hommel-Fontaine, J. Guitton, K. Slimane, B. You
Journal: Annals of Oncology (2014)
Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161–75
Authors: Laura Evangelista, Stefano Fanti, Maria Picchio
Journal: European Urology (2016)
Molecular and immunologycal basis of a novel therapeutic formulation: Oligoelements Zn, Se and Mn plus <i>Lachesis Muta</i> venom (O-LM)
Authors: E. J. Crescenti, M. Croci, G. Cremaschi, A. Genaro, N. Mohamad, L. Sambuco, V. Medina, R. Bergoc, E. S. Rivera
Journal: Journal of Clinical Oncology (2006)

13158 Background: We have previously reported that O-LM inhibited malignant cell proliferation in vitro and in vivo, increasing survival in rodent tumor models. We also demonstrated a protective action of O-LM against undesirable effects of chemotherapy and ionizing radiation, enhancing their therapeutic action. Furthermore, O-LM applied to patients with advanced breast, colon and pancreatic cancer resulted in increased survival and better quality of life with no side effects. In this work we further investigated the mechanisms involved in O-LM therapeutic effect. Methods: Two groups of Nude mice, control and O-LM (Zn, Se, Mn 4μ g/ml each; L. Muta 4 ng/ml) treated (0.1 ml/day, sc) were inoculated with PANC-1 cells to evaluate tumor development. PCNA, P53, antioxidant enzymes, apoptosis, microvessels and immune cell markers were studied by immunohistochemistry. In control and O-LM treated BALB/c mice we determined in vitro responses to T and B selective mitogens. Results: O-LM treated tumors showed significant lower growing rate, smaller mass (3,77±0,95 vs 9,75±2,30 cm 3 ) and an important peritumoral lymphoid infiltrate. Apoptotic cells and P53 expression were increased while PCNA was negative and microvessels counts were lower than controls. O-LM produced a 3-fold increase in Superoxide Dismutase activity. The infiltrates showed an important number of CD11 bearing cells and B220 positive but CD3 and CD19 negative cells, suggesting the presence of NK cells. In BALB/c mice T selective mitogen Con A, but not B selective mitogens responses were enhanced, with a maximum after 60 days of O-LM treatment. A 4-fold increase in IFNγ release was observed in cell-free supernatants from lymph node culture stimulated with Con A obtained from 60-days treated mice. Conclusions: Present data demonstrate the capacity of O-LM to modulate free radical production, the expression of tumor markers and suggest an important up-regulation of innate and T-cell mediated immunity induced by in vivo treatment with O-LM. These results reinforce the hypothesis that the effective therapeutic action of O-LM is based on its ability of targeting simultaneously multiple pathways involved in cancer development with the additional advantage of the total absence of adverse effects. No significant financial relationships to disclose.
Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database
Authors: Carol Coupland, Trevor Hill, Richard Morriss, Michael Moore, Antony Arthur, Julia Hippisley-Cox
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To assess associations between different antidepressant treatments and rates of three cardiovascular outcomes (myocardial infarction, stroke or transient ischaemic attack, and arrhythmia) in people with depression. <b>Design</b>&nbsp;Cohort study. <b>Setting</b>&nbsp;UK general practices contributing to the QResearch primary care database. <b>Participants</b>&nbsp;238 963 patients aged 20 to 64 years with a first diagnosis of depression between 1 January 2000 and 31 July 2011. <b>Exposures</b>&nbsp;Antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, duration of use, and commonly prescribed individual antidepressant drugs. <b>Main outcome measures</b>&nbsp;First diagnoses of myocardial infarction, stroke or transient ischaemic attack, and arrhythmia during five years' follow-up. Cox proportional hazards models were used to estimate hazard ratios, adjusting for potential confounding variables. <b>Results</b>&nbsp;During five years of follow-up, 772 patients had a myocardial infarction, 1106 had a stroke or transient ischaemic attack, and 1452 were diagnosed as having arrhythmia. No significant associations were found between antidepressant class and myocardial infarction over five years' follow-up. In the first year of follow-up, patients treated with selective serotonin reuptake inhibitors had a significantly reduced risk of myocardial infarction (adjusted hazard ratio 0.58, 95% confidence interval 0.42 to 0.79) compared with no use of antidepressants; among individual drugs, fluoxetine was associated with a significantly reduced risk (0.44, 0.27 to 0.72) and lofepramine with a significantly increased risk (3.07, 1.50 to 6.26). No significant associations were found between antidepressant class or individual drugs and risk of stroke or transient ischaemic attack. Antidepressant class was not significantly associated with arrhythmia over five years' follow-up, although the risk was significantly increased during the first 28 days of treatment with tricyclic and related antidepressants (adjusted hazard ratio 1.99, 1.27 to 3.13). Fluoxetine was associated with a significantly reduced risk of arrhythmia (0.74, 0.59 to 0.92) over five years, but citalopram was not significantly associated with risk of arrhythmia even at high doses (1.11, 0.72 to 1.71 for doses ≥40 mg/day). <b>Conclusions</b>&nbsp;This study found no evidence that selective serotonin reuptake inhibitors are associated with an increased risk of arrhythmia or stroke/transient ischaemic attack in people diagnosed as having depression between the ages of 20 to 64 or that citalopram is associated with a significantly increased risk of arrhythmia. It found some indication of a reduced risk of myocardial infarction with selective serotonin reuptake inhibitors, particularly fluoxetine, and of an increased risk with lofepramine.
ATPS-82PROBING THE TUMORIGENIC PROPERTIES OF TWO PORE POTASSIUM CHANNELS USING INHIBITORY KCNK9 mAbs
Authors: Han Sun, Liqun Luo, Bachchu Lal, Xinrong Ma, Lieping Chen, Amy Fulton, Daniel Leahy, John Laterra, Min Li
Journal: Neuro-Oncology (2015)

Ion channels govern portals that facilitate ionic passage across membranes in all organisms. KCNK9, a member of the family of two-pore domain potassium K+ channels, mediates leak currents critical to maintaining cell resting membrane potentials. Since its identification, KCNK9 has been implicated in various human disorders including cancer. KCNK9 overexpression has been observed in melanoma, colorectal, breast and lung cancers, and KCNK9 has been found to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here, we describe the development of novel monoclonal antibodies directed against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding, inhibits KCNK9 activity by inducing internalization of cell-surface channels. When tested on KCNK9-expressing cells, Y4 reduces cell viability; increases cell death and triggers complement-dependent cytotoxicity. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and breast cancer metastasis in a syngeneic murine model (P < 0.05). Since KCNK9 expression has been reported in human glioma and linked to regulation of glioblastoma cell survival, we extended our study to glioblastoma and examined KCNK9 expression in a panel of glioblastoma cell lines as well as primary cultures from patient-derived tumors. We found abundant KCNK9 expression in some aggressive glioblastoma models (e.g. Mayo39). We are currently investigating the functional effects of antibodies in these models. In conclusion, we have generated a high affinity KCNK9-specific monoclonal antibody that inhibits tumor cell survival, primary tumor formation and metastasis. Antibody-based KCNK9 targeting can shed light on KCNK9's significance in glioblastoma development and become promising therapeutic strategy in KCNK9-expressing brain malignancy.
Health Related Quality of Life in the Major Liver Conditions
Authors: P Cortesi, L Scalone, R Ciampichini, P Cozzolino, G Cesana, L Mantovani, S Okolicsanyi, A Ciaccio, M Rota, M Gentiluomo, M Gemma, A Grisolia, P Pontisso, P Burra, M Mondelli, L Fabris, M Colledan, S Fagiuoli, M Valsecchi, L Belli, M Strazzabosco
Journal: Hepatology (2013)
MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7
Authors: Xiao Yue, Dechen Cao, FengMing Lan, Qiang Pan, Tingyi Xia, Huiming Yu
Journal: Neuro-Oncology (2016)

miR-301a is frequently dysregulated and specific to human tumors, playing a critical role in tumorigenesis; however, the exact functions and regulatory mechanisms of miR-301a in glioma cells remain largely unknown. Herein, we show that miR-301a activated by the Wnt/β-catenin pathway promoted the invasion of glioma cells by directly targeting SEPT7.Biochemical, luciferase reporter, and hromatin immunoprecipitation PCR assays characterized the function and regulatory mechanisms of miR-301a in glioma invasion.Initially, we detected the expression of miR-301a in glioma tissues and identified that miR-301a had increased, with ascending grades of the tumor. Furthermore, high levels of miR-301a were associated with a poorer prognosis in glioma patients. It is important to note that the Wnt/β-catenin/TCF4 pathway enhanced miR-301a expression by binding to the promoter region. To determine the oncogenic functions of miR-301a in glioma, SEPT7 was supported as the direct target gene. In addition, the Wnt/β-catenin pathway repressed SEPT7 expression, which was dependent on miR-301a in glioma cells. Finally, miR-301a was activated by Wnt/β-catenin and then promoted invasion of glioma cells by inhibiting the expression of SEPT7 in vitro and in vivo.Our findings revealed the mechanism of action for miR-301a in tumor cell invasion. Moreover, the Wnt/miR-301a/SEPT7 signaling axis might be a novel target in treating glioma.
Effect of volume expansion on the paracellular flux of lanthanum in the proximal tubule.
Authors: C R Ramsey, T J Berndt, F G Knox
Journal: Journal of the American Society of Nephrology (1998)

Although studies of volume expansion (VE) in the Necturus suggest a major role for paracellular flux in reabsorption by the proximal tubule, results from morphologic or electrophysiologic studies of the effect of VE on the rat proximal tubule suggest only a minor role for paracellular transport. In the present study, during in vivo microperfusion, lanthanum was used as an extracellular marker to determine bidirectional paracellular flux in the rat proximal tubule before and during 10% VE. Lanthanum itself did not affect proximal tubule reabsorption (delta 0.7 +/- 3.3 nl/min, LaCl3 versus saline infusion, n = 7). When lanthanum was added to the luminal perfusate, paracellular lanthanum efflux from the lumen to the interstitium was 28.9 +/- 6.6 pg/min per mm, n = 7. Subsequent VE significantly decreased the paracellular lumen-to-interstitium efflux to 12.8 +/- 8.3 pg/min per mm concomitant with a 49% decrease in proximal fluid reabsorption (delta -2.6 +/- 0.9 nl/min per mm, P < 0.05). When lanthanum was infused interstitially, by means of a chronically implanted matrix, there was significant paracellular lanthanum influx from the interstitium into the lumen (143.9 +/- 18.6 pg/min per mm, n = 4). Subsequent VE significantly increased this interstitium-to-lumen influx to 212.1 +/- 29.2 pg/min per mm as proximal reabsorption was significantly decreased by 58% (delta -2.8 +/- 0.8 nl/min per mm, P < 0.05). Thus, VE affects bidirectional paracellular flux in a manner that would decrease proximal reabsorption; paracellular efflux from the lumen to the interstitium was decreased, whereas paracellular influx from the interstitium to the lumen was increased.
Leishmaniasis emergence in Europe
Authors: P D Ready
Journal: Eurosurveillance (2010)

Leishmaniasis emergence in Europe is reviewed, based on a search of literature up to and including 2009. Topics covered are the disease, its relevance, transmission and epidemiology, diagnostic methods, treatment, prevention, current geographical distribution, potential factors triggering changes in distribution, and risk prediction. Potential factors triggering distribution changes include vectorial competence, importation or dispersal of vectors and reservoir hosts, travel, and climatic/environmental change. The risk of introducing leishmaniasis into the European Union (EU) and its spread among Member States was assessed for the short (2-3 years) and long term (15-20 years). There is only a low risk of introducing exotic Leishmania species because of the absence of proven vectors and/or reservoir hosts. The main threat comes from the spread of the two parasites endemic in the EU, namely Leishmania infantum, which causes zoonotic visceral and cutaneous leishmaniasis in humans and the domestic dog (the reservoir host), and L. tropica, which causes anthroponotic cutaneous leishmaniasis. The natural vector of L. tropica occurs in southern Europe, but periodic disease outbreaks in Greece (and potentially elsewhere) should be easily contained by surveillance and prompt treatment, unless dogs or other synanthropic mammals prove to be reservoir hosts. The northward spread of L. infantum from the Mediterranean region will depend on whether climate and land cover permit the vectors to establish seasonal biting rates that match those of southern Europe. Increasing dog travel poses a significant risk of introducing L. infantum into northern Europe, and the threat posed by non-vectorial dog-to-dog transmission should be investigated.
Screening for Possible Drug Carcinogenicity: Second Report of Findings&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Gary D. Friedman, M.D., M.S, Hans K. Ury, Ph.D.
Journal: JNCI Journal of the National Cancer Institute (1983)

Cancer development was followed up through 1978 in 143,574 outpatients who were identified on the basis of computer-stored drug-dispensing data as users of various medicinal drugs during the 4-year period starting in July 1969. Screening analyses were repeated for the 95 most commonly used drugs and drug groups, which were reported previously after a shorter follow-up, and it was found that several drugcancer associations had either gained or lost statistical significance since the report. Screening of 120 additional less commonly used drugs revealed one negative and 43 positive drug-cancer associations. A few of these associations suggested interesting new hypotheses about possible drug effects, but further study is required before conclusions on causality can be drawn. The absence of association with cancer for many drugs provides some provisional assurance for the absence of carcinogenicity, but further follow-up is needed to rule out later effects.
Excess Mortality among Persons with Type 2 Diabetes
Authors: Mauro Tancredi, Annika Rosengren, Ann-Marie Svensson, Mikhail Kosiborod, Aldina Pivodic, Soffia Gudbjörnsdottir, Hans Wedel, Mark Clements, Sofia Dahlqvist, Marcus Lind
Journal: New England Journal of Medicine (2015)

The excess risks of death from any cause and death from cardiovascular causes among persons with type 2 diabetes and various levels of glycemic control and renal complications are unknown. In this registry-based study, we assessed these risks according to glycemic control and renal complications among persons with type 2 diabetes.We included patients with type 2 diabetes who were registered in the Swedish National Diabetes Register on or after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. All the participants were followed until December 31, 2011, in the Swedish Registry for Cause-Specific Mortality.The mean follow-up was 4.6 years in the diabetes group and 4.8 years in the control group. Overall, 77,117 of 435,369 patients with diabetes (17.7%) died, as compared with 306,097 of 2,117,483 controls (14.5%) (adjusted hazard ratio, 1.15; 95% confidence interval [CI], 1.14 to 1.16). The rate of cardiovascular death was 7.9% among patients versus 6.1% among controls (adjusted hazard ratio, 1.14; 95% CI, 1.13 to 1.15). The excess risks of death from any cause and cardiovascular death increased with younger age, worse glycemic control, and greater severity of renal complications. As compared with controls, the hazard ratio for death from any cause among patients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (≤52 mmol per mole of nonglycated hemoglobin) was 1.92 (95% CI, 1.75 to 2.11); the corresponding hazard ratio among patients older than 75 years of age or older was 0.95 (95% CI, 0.94 to 0.96). Among patients with normoalbuminuria, the hazard ratio for death among those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared with controls, was 1.60 (95% CI, 1.40 to 1.82); the corresponding hazard ratio among patients older than 75 years of age or older was 0.76 (95% CI, 0.75 to 0.78), and patients 65 to 75 years of age also had a significantly lower risk of death (hazard ratio, 0.87; 95% CI, 0.84 to 0.91).Mortality among persons with type 2 diabetes, as compared with that in the general population, varied greatly, from substantial excess risks in large patient groups to lower risks of death depending on age, glycemic control, and renal complications. (Funded by the Swedish government and others.).